$PALI News

Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative Colitis

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis Symposium

Palisade Bio to Participate in the Jefferies Global Healthcare Conference

Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

Palisade Bio Files Prospectus To Offer And Sell Up To $300M Of Securities

Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026

Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Palisade Bio's Data From Its Lead Program, PALI-2108, Selected For Poster Presentation At Digestive Disease Week 2026